Monoclonal Antibodies for Waldenström Macroglobulinemia
- 21 July 2018
- journal article
- research article
- Published by Elsevier BV in Hematology/Oncology Clinics of North America
- Vol. 32 (5), 841-852
- https://doi.org/10.1016/j.hoc.2018.05.010
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based AnalysisThe Oncologist, 2016
- Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunityOncoImmunology, 2014
- Antibody therapy of cancerNature Reviews Cancer, 2012
- The clinical application of monoclonal antibodies in chronic lymphocytic leukemiaBlood, 2010
- Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemiaLaboratory Investigation, 2009
- The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for TherapyThe Oncologist, 2008
- From the bench to the bedside: ways to improve rituximab efficacyBlood, 2004
- CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s MacroglobulinemiaJournal of Immunotherapy, 2001
- Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activityAnnals of Oncology, 1999
- Retention of B-cell-specific monoclonal antibodies by human lymphoma cellsBlood, 1994